CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis
Rationale: Cystic fibrosis (CF), caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, leads to impaired pancreatic function and therefore reduced intestinal absorption of lipids and fat-soluble vitamins especially in patients with CF developing pancreatic insuf...
Main Authors: | Olaf Sommerburg, Susanne Hämmerling, S. Philipp Schneider, Jürgen Okun, Claus-Dieter Langhans, Patricia Leutz-Schmidt, Mark O. Wielpütz, Werner Siems, Simon Y. Gräber, Marcus A. Mall, Mirjam Stahl |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Antioxidants |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3921/10/3/483 |
Similar Items
-
Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy
by: Connett GJ
Published: (2019-07-01) -
Activity of lumacaftor is not conserved in zebrafish Cftr bearing the major cystic fibrosis‐causing mutation
by: Onofrio Laselva, et al.
Published: (2019-10-01) -
Computed Tomographic Changes in Patients with Cystic Fibrosis Treated by Combination Therapy with Lumacaftor and Ivacaftor
by: François Arnaud, et al.
Published: (2021-05-01) -
Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation
by: Isabelle Sermet-Gaudelus
Published: (2013-03-01) -
Treatment of Cystic Fibrosis Patients Homozygous for <i>F508del</i> with Lumacaftor-Ivacaftor (Orkambi<sup>®</sup>) Restores Defective CFTR Channel Function in Circulating Mononuclear Cells
by: Maria Favia, et al.
Published: (2020-03-01)